In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

This study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma. It is an early exploratory clinical study evaluating the safety, tolerability, and preliminary efficacy of PICX Injection, an in vivo prepared CAR-T cell therapy, in the treatment of relapsed or refractory multiple myeloma.

Trial Details

NCT ID
NCT07715630
Phase
PHASE1
Sponsor
Chongqing Precision Biotech Co., Ltd
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Invivo CAR-T
Locations (sample)
  • Kunming, Yunnan, China|25.03889,102.71833

Key Eligibility Criteria

  • Age ≥ 18 years, male or female;
  • Confirmed diagnosis of multiple myeloma meeting at least one of the following criteria:
  • Disease progression after at least 2 prior standard treatment regimens; or poor response to primary therapeutic agents (e.g., immunomodulatory agen…
  • Disease progression within 18 months after first-line therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →